The Chemours Company (NYSE:CC) Stock Has Average Price Target of $17.73

The Chemours Company (NYSE:CC) has been given a consensus rating of “Hold” by the thirteen ratings firms that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and three have assigned a buy rating to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $17.73.

Several research firms have recently weighed in on CC. Weiss Ratings cut shares of Chemours from a “sell (d)” rating to a “sell (d-)” rating in a report on Thursday, August 6th. Barclays began coverage on Chemours in a research report on Monday, October 12th. They issued an “equal weight” rating and a $16.00 price objective on the stock. UBS Group dropped their price objective on Chemours from $18.00 to $16.00 and set a “neutral” rating for the company in a research note on Monday, October 5th. JPMorgan Chase & Co. reduced their target price on Chemours from $22.00 to $15.00 and set a “neutral” rating for the company in a research report on Thursday, August 13th. Finally, Mizuho lowered Chemours from an “outperform” rating to a “neutral” rating and decreased their target price for the stock from $18.00 to $15.00 in a research note on Wednesday, October 14th.

Chemours Price Performance

CC stock opened at $13.09 on Wednesday. The firm has a 50 day moving average of $14.12 and a 200-day moving average of $18.25. The company has a current ratio of 1.66, a quick ratio of 0.88 and a debt-to-equity ratio of 18.98. Chemours has a 12 month low of $10.44 and a 12 month high of $28.67. The firm has a market capitalization of $1.97 billion, a P/E ratio of -12.83 and a beta of 1.47.

Chemours (NYSE:CC) last posted its earnings results on Monday, November 2nd. The specialty chemicals company reported $0.21 earnings per share for the quarter, missing analysts’ consensus estimates of $0.26 by ($0.05). Chemours had a positive return on equity of 78.76% and a negative net margin of 2.64%. The firm had revenue of $1.54 billion for the quarter, compared to the consensus estimate of $1.53 billion. During the same period last year, the company posted $0.40 EPS. The business’s revenue was up 3.0% on a year-over-year basis. As a group, sell-side analysts predict that Chemours will post 0.83 earnings per share for the current fiscal year.

Chemours Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 15th. Stockholders of record on Monday, November 16th will be issued a dividend of $0.0875 per share. The ex-dividend date of this dividend is Monday, November 16th. This represents a $0.35 annualized dividend and a dividend yield of 2.7%. Chemours’s payout ratio is presently -18.32%.

Key Stories Impacting Chemours

Here are the key news stories impacting Chemours this week:

• Positive Sentiment: Chemours launched Faizeon two-phase liquid-cooling fluids for AI and high-performance-computing data centers, targeting a growing market with products designed to reduce energy and water use. The commercial opportunity is promising, though the announcement did not quantify expected revenue. Chemours launches Faizeon cooling solutions
• Positive Sentiment: Fourth-quarter revenue guidance of $1.7 billion–$1.8 billion is above the cited analyst consensus of $1.4 billion. Full-year 2026 revenue guidance of $5.9 billion is in line with consensus. Chemours reports third-quarter results
• Neutral Sentiment: Goldman Sachs maintained a Hold rating and a $16 price target, citing strong third-quarter results but offsetting concerns about weak volumes and a cautious fourth-quarter outlook. Goldman Sachs maintains Hold rating
• Negative Sentiment: Third-quarter adjusted EPS was $0.21, missing the $0.26 consensus and down from $0.40 a year earlier. Revenue of $1.54 billion slightly exceeded the $1.53 billion estimate, but the earnings shortfall and year-over-year profit decline could keep pressure on sentiment. Chemours third-quarter earnings coverage
• Negative Sentiment: A securities class action has been filed against Chemours and certain officers over alleged misleading statements during February 20–August 4, 2026, including claims concerning Opteon demand. The allegations are unproven, but the case adds legal and reputational risk; the lead-plaintiff deadline is December 7. Class action filing announcement

Insider Buying and Selling

In related news, insider Calderon Gerardo Familiar purchased 1,935 shares of the firm’s stock in a transaction dated Wednesday, August 12th. The shares were purchased at an average price of $15.53 per share, with a total value of $30,050.55. Following the acquisition, the insider directly owned 58,547 shares of the company’s stock, valued at approximately $909,234.91. This represents a 3.42% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Shane Hostetter acquired 3,350 shares of the stock in a transaction dated Thursday, August 6th. The shares were bought at an average price of $14.94 per share, for a total transaction of $50,049.00. Following the transaction, the chief financial officer owned 102,698 shares in the company, valued at approximately $1,534,308.12. This represents a 3.37% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders have purchased 8,663 shares of company stock worth $130,601. Insiders own 0.85% of the company’s stock.

Institutional Investors Weigh In On Chemours

Large investors have recently added to or reduced their stakes in the company. BlackRock Inc. bought a new stake in Chemours during the second quarter worth about $477,769,000. Wolf Hill Capital Management LP purchased a new position in shares of Chemours in the 2nd quarter worth about $59,698,056. Bank of New York Mellon Corp bought a new position in shares of Chemours during the 2nd quarter valued at about $33,353,000. Bank of America Corp DE lifted its position in Chemours by 79.1% in the 1st quarter. Bank of America Corp DE now owns 1,317,003 shares of the specialty chemicals company’s stock worth $29,014,000 after buying an additional 581,621 shares during the last quarter. Finally, Legal & General Group Plc bought a new stake in Chemours in the 2nd quarter worth approximately $28,400,000. Hedge funds and other institutional investors own 76.26% of the company’s stock.

About Chemours

The Chemours Company (NYSE: CC) is a global chemistry company that develops and manufactures performance chemicals and advanced materials for industrial and consumer applications. The company serves customers in markets including automotive, construction, energy, electronics, healthcare, and general manufacturing.

Chemours operates through businesses focused on Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. Its products include titanium dioxide pigments used to provide whiteness and opacity in coatings, plastics, and paper; refrigerants and related thermal-management solutions; and high-performance fluoropolymers and specialty materials sold under brands such as Teflon™, Viton™, and Nafion™.

Headquartered in Wilmington, Delaware, Chemours serves customers globally through manufacturing facilities, research and development operations, and commercial activities across North America, Latin America, Europe, and Asia-Pacific.